Among patients with SCH, there is a notable propensity for progression to clinically overt hypothyroidism, occurring at a rate of 2.6% annually in those with negative anti-TPO antibodies and 4.3% in those with positive anti-TPO antibodies [8, 30]. This evidence concerns the gene TPO and spindle cell hemangioma.